http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 12 Mar 2026 16:46:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Dickinson+Andrew+D/26154077.html si-local-file:///var/storage/secattach/20260312/26154077.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Dickinson+Andrew+D/26154077.html Thu, 12 Mar 2026 16:46:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Dickinson+Andrew+D/26154077.html si-local-file:///var/storage/secattach/20260312/26154077.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Dickinson+Andrew+D/26154077.html Thu, 12 Mar 2026 16:46:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Mercier+Johanna/26154012.html si-local-file:///var/storage/secattach/20260312/26154012.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Mercier+Johanna/26154012.html Thu, 12 Mar 2026 16:42:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Mercier+Johanna/26154012.html si-local-file:///var/storage/secattach/20260312/26154012.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Mercier+Johanna/26154012.html Thu, 12 Mar 2026 16:42:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Cain+Wettan+Keeley+M/26153963.html si-local-file:///var/storage/secattach/20260312/26153963.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Cain+Wettan+Keeley+M/26153963.html Thu, 12 Mar 2026 16:40:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Cain+Wettan+Keeley+M/26153963.html si-local-file:///var/storage/secattach/20260312/26153963.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Cain+Wettan+Keeley+M/26153963.html Thu, 12 Mar 2026 16:40:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Burkhart+Erin/26153918.html si-local-file:///var/storage/secattach/20260312/26153918.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Burkhart+Erin/26153918.html Thu, 12 Mar 2026 16:38:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Burkhart+Erin/26153918.html si-local-file:///var/storage/secattach/20260312/26153918.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Burkhart+Erin/26153918.html Thu, 12 Mar 2026 16:38:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+O%26apos%3BDay+Daniel+Patrick/26153585.html si-local-file:///var/storage/secattach/20260312/26153585.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+O%26apos%3BDay+Daniel+Patrick/26153585.html Thu, 12 Mar 2026 16:26:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+O%26apos%3BDay+Daniel+Patrick/26153585.html si-local-file:///var/storage/secattach/20260312/26153585.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+O%26apos%3BDay+Daniel+Patrick/26153585.html Thu, 12 Mar 2026 16:26:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Berger+Dietmar/26153522.html si-local-file:///var/storage/secattach/20260312/26153522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Berger+Dietmar/26153522.html Thu, 12 Mar 2026 16:23:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Berger+Dietmar/26153522.html si-local-file:///var/storage/secattach/20260312/26153522.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Mar+10++Filed+by%3A+Berger+Dietmar/26153522.html Thu, 12 Mar 2026 16:23:00 -0400 GILD O.00092067 http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Amgen (NASDAQ: AMGN) with a Hold rating and a price target of $350.00.</p><p>The analyst comments "We think AMGN's stock is fairly valued at current lvls: 1) the $9.9Bn LOE gap can be offset by base business growth, 2) upside from here hinges on bull case for cardiometabolic pipeline MariTide + olpasiran (we can't rule out >30% vomiting in MariTide Ph3 & think ola can show 15~20% MACE RR but are skeptical on broad market uptake), 3) that said, several programs are underappreciated (Uplizna IgG4-RD, Tezspire COPD, http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html Tue, 10 Mar 2026 05:38:49 -0400 AMGN GILD VRTX http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Amgen (NASDAQ: AMGN) with a Hold rating and a price target of $350.00.</p><p>The analyst comments "We think AMGN's stock is fairly valued at current lvls: 1) the $9.9Bn LOE gap can be offset by base business growth, 2) upside from here hinges on bull case for cardiometabolic pipeline MariTide + olpasiran (we can't rule out >30% vomiting in MariTide Ph3 & think ola can show 15~20% MACE RR but are skeptical on broad market uptake), 3) that said, several programs are underappreciated (Uplizna IgG4-RD, Tezspire COPD, http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html Tue, 10 Mar 2026 05:38:49 -0400 AMGN GILD VRTX http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Amgen (NASDAQ: AMGN) with a Hold rating and a price target of $350.00.</p><p>The analyst comments "We think AMGN's stock is fairly valued at current lvls: 1) the $9.9Bn LOE gap can be offset by base business growth, 2) upside from here hinges on bull case for cardiometabolic pipeline MariTide + olpasiran (we can't rule out >30% vomiting in MariTide Ph3 & think ola can show 15~20% MACE RR but are skeptical on broad market uptake), 3) that said, several programs are underappreciated (Uplizna IgG4-RD, Tezspire COPD, http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html Tue, 10 Mar 2026 05:38:49 -0400 AMGN GILD VRTX http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Amgen (NASDAQ: AMGN) with a Hold rating and a price target of $350.00.</p><p>The analyst comments "We think AMGN's stock is fairly valued at current lvls: 1) the $9.9Bn LOE gap can be offset by base business growth, 2) upside from here hinges on bull case for cardiometabolic pipeline MariTide + olpasiran (we can't rule out >30% vomiting in MariTide Ph3 & think ola can show 15~20% MACE RR but are skeptical on broad market uptake), 3) that said, several programs are underappreciated (Uplizna IgG4-RD, Tezspire COPD, http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html Tue, 10 Mar 2026 05:38:49 -0400 AMGN GILD VRTX http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Amgen (NASDAQ: AMGN) with a Hold rating and a price target of $350.00.</p><p>The analyst comments "We think AMGN's stock is fairly valued at current lvls: 1) the $9.9Bn LOE gap can be offset by base business growth, 2) upside from here hinges on bull case for cardiometabolic pipeline MariTide + olpasiran (we can't rule out >30% vomiting in MariTide Ph3 & think ola can show 15~20% MACE RR but are skeptical on broad market uptake), 3) that said, several programs are underappreciated (Uplizna IgG4-RD, Tezspire COPD, http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html Tue, 10 Mar 2026 05:38:49 -0400 AMGN GILD VRTX http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Amgen (NASDAQ: AMGN) with a Hold rating and a price target of $350.00.</p><p>The analyst comments "We think AMGN's stock is fairly valued at current lvls: 1) the $9.9Bn LOE gap can be offset by base business growth, 2) upside from here hinges on bull case for cardiometabolic pipeline MariTide + olpasiran (we can't rule out >30% vomiting in MariTide Ph3 & think ola can show 15~20% MACE RR but are skeptical on broad market uptake), 3) that said, several programs are underappreciated (Uplizna IgG4-RD, Tezspire COPD, http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Amgen+%28AMGN%29+at+Hold/26134510.html Tue, 10 Mar 2026 05:38:49 -0400 AMGN GILD VRTX http://www.streetinsider.com/Hot+New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Vertex (NASDAQ: VRTX) with a Buy rating and a price target of $580.00.</p><p>The analyst comments "We're Buy on VRTX given: 1) CF is a stable franchise for VRTX w/ limited competitive threats & supports floor valuation of ~$422 (CF NPV + cash), 2) although pove's Ph.3 IgAN data came in line w/ sibe, IgAN market is large & pove auto-injector format could improve compliance, 3) we think Inaxaplin could show best-in-class data in AMKD, 4) while we're mixed on pain due to pbo risk in DPN http://www.streetinsider.com/Hot+New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html Tue, 10 Mar 2026 05:38:24 -0400 AMGN GILD VRTX http://www.streetinsider.com/Hot+New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Vertex (NASDAQ: VRTX) with a Buy rating and a price target of $580.00.</p><p>The analyst comments "We're Buy on VRTX given: 1) CF is a stable franchise for VRTX w/ limited competitive threats & supports floor valuation of ~$422 (CF NPV + cash), 2) although pove's Ph.3 IgAN data came in line w/ sibe, IgAN market is large & pove auto-injector format could improve compliance, 3) we think Inaxaplin could show best-in-class data in AMKD, 4) while we're mixed on pain due to pbo risk in DPN http://www.streetinsider.com/Hot+New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html Tue, 10 Mar 2026 05:38:24 -0400 AMGN GILD VRTX http://www.streetinsider.com/Hot+New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Vertex (NASDAQ: VRTX) with a Buy rating and a price target of $580.00.</p><p>The analyst comments "We're Buy on VRTX given: 1) CF is a stable franchise for VRTX w/ limited competitive threats & supports floor valuation of ~$422 (CF NPV + cash), 2) although pove's Ph.3 IgAN data came in line w/ sibe, IgAN market is large & pove auto-injector format could improve compliance, 3) we think Inaxaplin could show best-in-class data in AMKD, 4) while we're mixed on pain due to pbo risk in DPN http://www.streetinsider.com/Hot+New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html Tue, 10 Mar 2026 05:38:24 -0400 AMGN GILD VRTX http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Vertex (NASDAQ: VRTX) with a Buy rating and a price target of $580.00.</p><p>The analyst comments "We're Buy on VRTX given: 1) CF is a stable franchise for VRTX w/ limited competitive threats & supports floor valuation of ~$422 (CF NPV + cash), 2) although pove's Ph.3 IgAN data came in line w/ sibe, IgAN market is large & pove auto-injector format could improve compliance, 3) we think Inaxaplin could show best-in-class data in AMKD, 4) while we're mixed on pain due to pbo risk in DPN http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html Tue, 10 Mar 2026 05:38:24 -0400 AMGN GILD VRTX http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Vertex (NASDAQ: VRTX) with a Buy rating and a price target of $580.00.</p><p>The analyst comments "We're Buy on VRTX given: 1) CF is a stable franchise for VRTX w/ limited competitive threats & supports floor valuation of ~$422 (CF NPV + cash), 2) although pove's Ph.3 IgAN data came in line w/ sibe, IgAN market is large & pove auto-injector format could improve compliance, 3) we think Inaxaplin could show best-in-class data in AMKD, 4) while we're mixed on pain due to pbo risk in DPN http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html Tue, 10 Mar 2026 05:38:24 -0400 AMGN GILD VRTX http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Vertex (NASDAQ: VRTX) with a Buy rating and a price target of $580.00.</p><p>The analyst comments "We're Buy on VRTX given: 1) CF is a stable franchise for VRTX w/ limited competitive threats & supports floor valuation of ~$422 (CF NPV + cash), 2) although pove's Ph.3 IgAN data came in line w/ sibe, IgAN market is large & pove auto-injector format could improve compliance, 3) we think Inaxaplin could show best-in-class data in AMKD, 4) while we're mixed on pain due to pbo risk in DPN http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html Tue, 10 Mar 2026 05:38:24 -0400 AMGN GILD VRTX http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html (Updated - March 10, 2026 5:38 AM EDT) <p>Jefferies analyst Akash Tewari initiates coverage on Vertex (NASDAQ: VRTX) with a Buy rating and a price target of $580.00.</p><p>The analyst comments "We're Buy on VRTX given: 1) CF is a stable franchise for VRTX w/ limited competitive threats & supports floor valuation of ~$422 (CF NPV + cash), 2) although pove's Ph.3 IgAN data came in line w/ sibe, IgAN market is large & pove auto-injector format could improve compliance, 3) we think Inaxaplin could show best-in-class data in AMKD, 4) while we're mixed on pain due to pbo risk in DPN http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Vertex+%28VRTX%29+at+Buy/26134512.html Tue, 10 Mar 2026 05:38:24 -0400 AMGN GILD VRTX